
    
      A Phase 1, First Time in Man Study to Evaluate the Safety, Tolerability, and Pharmacokinetics
      of NST-1024 in Healthy Subjects and Otherwise Healthy Subjects with Elevated Triglycerides.
      This will be a double-blind, randomised, placebo-controlled, single and multiple oral dose
      study conducted in 2 parts. In part A up to 6 cohorts of 8 healthy volunteers will receive
      single ascending doses of NST-1024 or matching placebo. I part B up to 4 cohorts of 10
      otherwise healthy volunteers, with elevated triglycerides will receive daily multiple
      ascending doses of NST-1024 for 14 days
    
  